Abstract
Background — Advances in neonatal intensive care have resulted in high survival rates for infants born with extremely low birth weight. Accordingly, the treatment and rehabilitation of premature neonates with bronchopulmonary dysplasia (BPD) is indisputably an urgent problem. Objective — To evaluate the efficacy of vibroacoustic therapy in patients with BPD in the complex of therapeutic measures. Material and Methods — The study was a prospective, non-randomized open-label controlled clinical trial conducted in 2018-2020 in Astana, Kazakhstan. It included 69 children with BPD hospitalized with a concomitant diagnosis of pneumonia between the ages of 1 and 2 years. The study subjects were distributed among two groups: Group 1 (the main group, n=37) receiving vibroacoustic therapy with the VibroLung apparatus in combination with the main treatment and Group 2 (the control, n=32) receiving solely the main treatment. Results — The inclusion of the vibroacoustic method of treatment in the combination therapy of pneumonia in children with BPD resulted in early leveling of the following clinical symptoms: a reduction in the duration of the high fever by 1.18 days vs. the control group (p<0.05), relief of respiratory failure 1.4 days earlier vs. the control group (p<0.05) and a decrease in the duration of inpatient treatment by 2.9 days, compared with the control group (p<0.05). All of these implied the efficacy of this treatment method. Conclusion — Our results demonstrated that vibroacoustic therapy was a relevant addition to the treatment of pneumonia in children with BPD.